Physician profile
Mark G Bamberger
NPI 1346274834
$6,998.47
in general payments reported to CMS, 2019-2025
52 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $432 · 2021: $740 · 2022: $1,153 · 2023: $1,308 · 2024: $1,333 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,865.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,285.16 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Lilly USA, LLC | $905.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $565.80 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $500.46 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $376.33 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $301.26 | 2022-2025 | |
| Pfizer INC. | $258.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.29 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $212.78 | 2019-2025 | Arexvy, Shingrix |
| Abbott Laboratories | $209.72 | 2019-2024 | Freestyle Libre 3, Eterna |
| Astrazeneca Pharmaceuticals LP | $200.41 | 2019-2025 | Farxiga, Fasenra, Airsupra |
| Janssen Pharmaceuticals, INC | $186.71 | 2019-2025 | Spravato |
| Exact Sciences Corporation | $161.19 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.28 | 2020-2024 | Xifaxan |
| Eisai INC. | $117.64 | 2020-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bamberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.